Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) CEO Jean-Pierre Sommadossi sold 33,941 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $4.05, for a total transaction of $137,461.05. Following the completion of the sale, the chief executive officer now owns 5,890,053 shares in the company, valued at $23,854,714.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Jean-Pierre Sommadossi also recently made the following trade(s):
- On Thursday, September 19th, Jean-Pierre Sommadossi sold 1,841 shares of Atea Pharmaceuticals stock. The stock was sold at an average price of $4.00, for a total transaction of $7,364.00.
Atea Pharmaceuticals Trading Down 3.9 %
Shares of NASDAQ:AVIR opened at $3.67 on Friday. The company has a market capitalization of $309.10 million, a price-to-earnings ratio of -1.87 and a beta of 0.18. Atea Pharmaceuticals, Inc. has a 12 month low of $2.77 and a 12 month high of $4.60. The firm’s 50-day moving average is $3.71 and its 200 day moving average is $3.72.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on AVIR shares. William Blair upgraded shares of Atea Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Morgan Stanley upgraded shares of Atea Pharmaceuticals from an “underweight” rating to an “equal weight” rating and boosted their target price for the stock from $2.00 to $6.88 in a report on Tuesday, August 13th.
Check Out Our Latest Stock Analysis on Atea Pharmaceuticals
Hedge Funds Weigh In On Atea Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in AVIR. Almitas Capital LLC bought a new position in Atea Pharmaceuticals during the 2nd quarter valued at about $4,271,000. Dimensional Fund Advisors LP grew its stake in Atea Pharmaceuticals by 55.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 594,360 shares of the company’s stock worth $1,968,000 after acquiring an additional 211,428 shares in the last quarter. Marshall Wace LLP bought a new position in Atea Pharmaceuticals in the 2nd quarter worth about $603,000. Vanguard Group Inc. grew its stake in Atea Pharmaceuticals by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 4,722,522 shares of the company’s stock worth $19,079,000 after acquiring an additional 122,812 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its stake in Atea Pharmaceuticals by 22.2% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 672,984 shares of the company’s stock worth $2,719,000 after acquiring an additional 122,447 shares in the last quarter. 86.67% of the stock is currently owned by institutional investors.
Atea Pharmaceuticals Company Profile
Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.
Featured Stories
- Five stocks we like better than Atea Pharmaceuticals
- The 3 Best Retail Stocks to Shop for in August
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Do ETFs Pay Dividends? What You Need to Know
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Investing in the High PE Growth Stocks
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.